OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Obsidian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.94+0.17 (+1.44%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Obsidian Therapeutics
Pharmaceutical Preparations, SIC 2834
Obsidian Therapeutics, Inc. is listed on Nasdaq under the ticker OBX, in the SEC industry Pharmaceutical Preparations.
Company profile
Company
- Legal name
- Obsidian Therapeutics, Inc.
- Headquarters
- Cambridge, MA
- Address
- 1030 Massachusetts Avenue 02138
- Phone
- (781) 806-6245
- Website
- obsidiantx.com
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- OBX
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2026
- Shares outstanding
- 62M, Aug 10, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2130606
- CUSIP
- 67448A106
- ISIN
- US67448A1060
- EIN
- 42-1977778
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Madan Jagasia | Chief Executive Officer, Director | – |
| Julie B. Feder | Chief Financial Officer | – |
| Parameswaran Hari | Chief Medical Officer | – |
| Matthew Norkunas | Director | 30,937 |
| Maria Fardis | Director | – |
| Peter Barrett | Director | – |
| Heidi Hagen | Director | – |
| Robert W. Ross | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 3, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 3, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 3, 2026 | Name change | Name changed from Gazelle Parent, Inc. to Obsidian Therapeutics, Inc. |
| Apr 22, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |